Teva Pharmaceutical Industries Target of Unusually Large Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of unusually large options trading activity on Monday. Investors bought 37,691 put options on the stock. This represents an increase of 38% compared to the average volume of 27,275 put options.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.12 during mid-day trading on Monday, reaching $22.21. The stock had a trading volume of 11,771,780 shares, compared to its average volume of 9,456,189. Teva Pharmaceutical Industries has a twelve month low of $10.34 and a twelve month high of $22.25. The business has a 50 day simple moving average of $17.89 and a 200 day simple moving average of $17.56. The firm has a market capitalization of $25.16 billion, a price-to-earnings ratio of -26.13, a PEG ratio of 0.99 and a beta of 0.79. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Barclays raised their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $20.88.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of the business. Thrivent Financial for Lutherans lifted its holdings in Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $24,314,000. Two Sigma Advisers LP increased its holdings in shares of Teva Pharmaceutical Industries by 15.3% in the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company's stock valued at $18,642,000 after purchasing an additional 137,000 shares in the last quarter. TCW Group Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $1,286,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Teva Pharmaceutical Industries by 24.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company's stock worth $16,203,000 after buying an additional 177,836 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.